GSK3β Inhibition Prevents Macrophage Reprogramming by High-Dose Methotrexate
Journal of Innate Immunity · 2023 · 15 (1) · 283-296
DOI: 10.1159/000526622 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Innate Immunity, online erschienen am 14.11.2022. Verfasst von Israel Ríos und 9 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Inmunometabolismo e Inflamación, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Ma…. Hauptthemen laut MEDLINE: Methotrexate, Macrophages. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Methotrexate (MTX) is an antifolate drug used as a chemotherapeutic agent for acute lymphoblastic leukemia, where MTX improves patients’ prognosis. Macrophage reprogramming is being increasingly assessed as an antitumor therapeutic strategy. However, and although MTX limits the pathogenic action of macrophages in chronic inflammatory diseases, its effects on tumor-promoting macrophages have not been previously explored. We now report that MTX shapes the transcriptional and functional profile of M-CSF-dependent human macrophages, whose transcriptome is highly enriched in the gene signature that defines pathogenic tumor-associated macrophages (“large TAM”). Specifically, MTX prompted the acquisition of the gene signature of antitumoral “small TAM” and skewed macrophages toward an IL-6high IFNβ1high IL-10low phenotype upon subsequent stimulation. Mechanistically, the MTX-induced macrophage reprogramming effect correlated with a reduction of the M-CSF receptor CSF1R expression and function, as well as a diminished expression of MAF and MAFB transcription factors, primary determinants of pro-tumoral macrophages whose transcriptional activity is dependent on GSK3β. Indeed, the ability of MTX to transcriptionally reprogram macrophages toward an antitumoral phenotype was abrogated by inhibition of GSK3β. Globally, our results establish MTX as a macrophage reprogramming drug and indicate that its ability to modulate macrophage polarization may also underlie its therapeutic benefits. Since GSK3β inhibition abrogates the reprogramming action of MTX, our results suggest that the GSK3β-MAFB/MAF axis constitutes a target for the macrophage-centered antitumor strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad de Inmunometabolismo e Inflamación, Instituto de Investigación Sanitaria Gregorio Marañón, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
- Departamento de Inmunología y Oncología, Centro Nacional de Biotecnología/Consejo Superior de Investigaciones Científicas, Madrid, Spain.
- Myeloid Cell Laboratory, Centro de Investigaciones Biológicas, Madrid, Spain.
- Department of Clinical Chemistry, Amsterdam University Medical Center, Amsterdam, The Netherlands.
- Department of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
Zitieren
APA
Ríos, I., López-Navarro, B., Torres-Torresano, M., Soler Palacios, B., Simón-Fuentes, M., Domínguez-Soto, Á., Muller, I. B., Jansen, G., Corbí, Á. L., & Puig-Kröger, A. (2023). GSK3β Inhibition Prevents Macrophage Reprogramming by High-Dose Methotrexate. Journal of Innate Immunity, 15(1), 283-296. https://doi.org/10.1159/000526622
Vancouver
Ríos I, López-Navarro B, Torres-Torresano M, Soler Palacios B, Simón-Fuentes M, Domínguez-Soto Á, et al. GSK3β Inhibition Prevents Macrophage Reprogramming by High-Dose Methotrexate. Journal of Innate Immunity. 2023;15(1):283-296. doi:10.1159/000526622
BibTeX
@article{Ros2023,
author = {Ríos, Israel and López-Navarro, Baltasar and Torres-Torresano, Mónica and Soler Palacios, Blanca and Simón-Fuentes, Miriam and Domínguez-Soto, Ángeles and Muller, Ittai B and Jansen, Gerrit and Corbí, Ángel L and Puig-Kröger, Amaya},
title = {GSK3β Inhibition Prevents Macrophage Reprogramming by High-Dose Methotrexate},
journal = {Journal of Innate Immunity},
year = {2023},
volume = {15},
number = {1},
pages = {283--296},
doi = {10.1159/000526622}
}
EUVIMED